Lessons learned from recent cardiovascular clinical trials: Part I

被引：83

作者：

DeMets, DL

Califf, RM

机构：

[1] Duke Univ, Med Ctr, Duke Clin Res Inst, Durham, NC 27715 USA

[2] Univ Wisconsin, Dept Biostat & Med Informat, Madison, WI USA

来源：

关键词：

D O I：

10.1161/01.CIR.0000023219.51483.66

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

[No abstract available]

引用

页码：746 / 751

页数：6

共 54 条

[1] [Anonymous], 1989, NEW ENGL J MED, V321, P406
[2] [Anonymous], 1988, LANCET, V2, P349
[3] *ASTR PHARM LP, 2002, FDA APPR ASTR TOPR X
[4] Bazzino O, 1998, NEW ENGL J MED, V338, P1498
[5] Bazzino O, 1998, NEW ENGL J MED, V338, P1488
[6] Califf RM, 1997, EUR HEART J, V18, P367
[7] Circadian rhythm and sudden death in heart failure - Results from Prospective Randomized Amlodipine Survival Trial
Carson, PA
O'Connor, CM
Miller, AB
Anderson, S
Belkin, R
Neuberg, GW
Wertheimer, JH
Frid, D
Cropp, A
Packer, M
[J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2000, 36 (02) : 541 - 546
[8] A dose-dependent increase in mortality with vesnarinone among patients with severe heart failure
Cohn, JN
Goldstein, SO
Greenberg, BH
Lorell, BH
Bourge, RC
Jaski, BE
Gottlieb, SO
McGrew, F
DeMets, DL
White, BG
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 1998, 339 (25) : 1810 - 1816
[9] Reliable assessment of the effects of treatment on mortality and major morbidity, I: clinical trials
Collins, R
MacMahon, S
[J]. LANCET, 2001, 357 (9253) : 373 - 380
[10] Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE):: a randomised trial against atenolol
Dahlöf, B
Devereux, RB
Kjeldsen, SE
Julius, S
Beevers, G
de Faire, U
Fyhrquist, F
Ibsen, H
Kristiansson, K
Lederballe-Pedersen, O
Lindholm, LH
Nieminen, MS
Omvik, P
Oparil, S
Wedel, H
[J]. LANCET, 2002, 359 (9311) : 995 - 1003